Revolutionizing treatment for patients in need

Scroll To Discover


We’re committed to delivering boundless therapeutic ingenuity

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that embodies the values of commitment, empowerment, and teamwork. We aim to bring novel therapeutics to patients across a range of conditions with limited treatment options.


Novel therapies, beginning with the eye

For the millions of patients living with Demodex blepharitis, an FDA-approved treatment is on the horizon.

News & Media

Here is the latest from Tarsus

03/31/2021 Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates
03/29/2021 Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease
01/19/2021 Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel
Contact Tarsus

Please reach out to us using the form below.

General Information
Investor Relations
Opt in to be the first to receive the latest Tarsus news
Contact Tarsus

Thank you for getting in touch! Someone from our team will respond shortly.